![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Comparison of Population Genotype and Ultradeep Sequencing Results from Subjects with Virologic Failure in ARIES: Impact of Low-abundance HIV Variants on Outcome
|
|
|
Reported by Jules Levin ICAAC Chicago 2011Sept 17-20
Lisa Ross1, Kathleen Squires2, Benjamin Young3, Edwin DeJesus4, Nicholas Bellos5, Daniel Murphy6, Henry Zhao1, Brian Wine1, Joseph Horton1, Mark Shaefer7
1GlaxoSmithKline, RTP, NC, USA; 2Thomas Jefferson Univ., Philadelphia, PA,USA; 3Rocky Mountain CARES/DIDC, Denver, CO, USA; Health Connections International, Amsterdam, Netherlands; 4Orlando Immunology Ctr., Orlando, FL, USA; 5SW Infectious Disease Assoc., Dallas, TX, USA; 6Clinique Medicale L'Actuel, Montreal, Canada; 7ViiV Healthcare, RTP, NC, USA
![ICAAC1.gif](../images/100911/100911-2/ICAAC1.gif)
![ICAAC2.gif](../images/100911/100911-2/ICAAC2.gif)
![ICAAC3.gif](../images/100911/100911-2/ICAAC3.gif)
![ICAAC4.gif](../images/100911/100911-2/ICAAC4.gif)
![ICAAC5.gif](../images/100911/100911-2/ICAAC5.gif)
![ICAAC6.gif](../images/100911/100911-2/ICAAC6.gif)
![ICAAC7.gif](../images/100911/100911-2/ICAAC7.gif)
![ICAAC8.gif](../images/100911/100911-2/ICAAC8.gif)
![ICAAC9.gif](../images/100911/100911-2/ICAAC9.gif)
![ICAAC10.gif](../images/100911/100911-2/ICAAC10.gif)
References
1. Squires KE, etal. Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients. HIV Clin Trials. 2010 Mar-Apr;11(2):69-79.
2. Squires KE, etal. Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients. AIDS. 2010 24 (13):2019-2027.
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|